CorMedix Inc. (CRMD)
Automate Your Wheel Strategy on CRMD
With Tiblio's Option Bot, you can configure your own wheel strategy including CRMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CRMD
- Rev/Share 2.8224
- Book/Share 4.9273
- PB 1.648
- Debt/Equity 0.398
- CurrentRatio 1.942
- ROIC 0.168
- MktCap 639767045.0
- FreeCF/Share 0.9801
- PFCF 8.5966
- PE 3.7942
- Debt/Assets 0.1983
- DivYield 0
- ROE 0.8183
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 1
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CRMD | D. Boral Capital | Hold | Buy | -- | $14 | Oct. 20, 2025 |
| Downgrade | CRMD | D. Boral Capital | Buy | Hold | -- | -- | June 30, 2025 |
| Initiation | CRMD | H.C. Wainwright | -- | Buy | -- | $20 | June 30, 2025 |
| Initiation | CRMD | Leerink Partners | -- | Outperform | -- | $18 | March 7, 2025 |
| Initiation | CRMD | D. Boral Capital | -- | Buy | -- | $15 | Jan. 13, 2025 |
| Initiation | CRMD | Rodman & Renshaw | -- | Buy | -- | $13 | Aug. 26, 2024 |
News
CRMD Down 31% in a Month: Is This an Indication to Sell the Stock?
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Negative
CorMedix sinks 31% in a month after cautious 2026 guidance for DefenCath points to slower adoption and pricing pressure, likely souring investor sentiment.
Read More
Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption?
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Negative
CorMedix's DefenCath drives revenues with strong adoption, but 2026 outlook signals slower growth, raising concerns over long-term adoption.
Read More
CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy?
Published: January 20, 2026 by: Zacks Investment Research
Sentiment: Positive
CRMD and MIRM are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
Read More
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026
Published: January 19, 2026 by: MarketBeat
Sentiment: Positive
Last year, the biotechnology industry leaned heavily into the power of artificial intelligence (AI), using machine learning models to identify drug targets, to optimize molecules, and to make key predictions about trial outcomes. Alongside the continued proliferation of technology within the drug development space, companies with a focus on obesity, rare diseases, and oncology applications saw commercial achievements.
Read More
Will DefenCath Continue to Aid CorMedix's Top Line in Q4 Earnings?
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Positive
CRMD's DefenCath, the only FDA-approved antimicrobial catheter lock, saw higher outpatient dialysis use in the fourth quarter, likely driving revenues.
Read More
Lost Money on CorMedix Inc. (CRMD)? Contact Levi & Korsinsky About Fraud Investigation
Published: January 14, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into CorMedix Inc. ("CorMedix Inc.") (NASDAQ: CRMD) concerning potential violations of the federal securities laws. On January 8, 2026, before the market opened, CorMedix published preliminary fourth quarter and full year 2025 results disclosing that its major revenue driver DefenCath would change its reimbursement policy change beginning on July 1, 2026.
Read More
Are Investors Undervaluing CorMedix (CRMD) Right Now?
Published: January 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?
Published: December 26, 2025 by: Zacks Investment Research
Sentiment: Positive
CRMD's $300M Melinta acquisition adds seven products and helps raise 2025 revenue guidance, but questions remain over easing DefenCath reliance.
Read More
Why CorMedix Could be the Biopharma Name to Watch Early in 2026
Published: December 23, 2025 by: MarketBeat
Sentiment: Neutral
An often overlooked risk for patients receiving dialysis for kidney failure or related conditions is infection. Unfortunately, infections among dialysis patients are both common and serious, presenting a significant complication and an unmet medical need.
Read More
CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy?
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Neutral
CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.
Read More
CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?
Published: December 11, 2025 by: Zacks Investment Research
Sentiment: Positive
CorMedix surges on strong DefenCath uptake as sales climb while the Melinta acquisition expands and diversifies its commercial portfolio.
Read More
Does CorMedix (CRMD) Have the Potential to Rally 68.74% as Wall Street Analysts Expect?
Published: December 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for CorMedix (CRMD) points to a 68.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
CorMedix (CRMD) Upgraded to Strong Buy: Here's What You Should Know
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
CorMedix (CRMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead?
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
CRMD's lead product, DefenCath, generates $167.6M in sales in the first nine months of 2025, with market exclusivity through 2033 likely to provide growth momentum.
Read More
CorMedix: Raised Guidance, NOL Confidence, And Rezzayo Optionality Justify A Hold Rating
Published: November 14, 2025 by: Seeking Alpha
Sentiment: Positive
CorMedix delivered strong Q3 results, with DefenCath outperforming expectations and near-term earnings power underestimated in prior analysis. CRMD raised FY25 guidance, but long-term risks remain due to TDAPA reimbursement changes, pricing pressure, and customer concentration. The Melinta acquisition and Rezzayo prophylaxis trial offer growth optionality, but Rezzayo's success is uncertain and pivotal for post-TDAPA prospects.
Read More
CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript
Published: November 12, 2025 by: Seeking Alpha
Sentiment: Neutral
CorMedix Inc. ( CRMD ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Joseph Todisco - CEO & Director Elizabeth Masson-Hurlburt - Executive VP, Chief Operating Officer & Chief Integration Officer Susan Blum - EVP & Chief Financial Officer Conference Call Participants Daniel Ferry - Lifesci Advisors, LLC Leszek Sulewski - Truist Securities, Inc., Research Division Jason Butler - Citizens JMP Securities, LLC, Research Division Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Serge Belanger - Needham & Company, LLC, Research Division Presentation Operator Good …
Read More
Wall Street Analysts Predict an 80.58% Upside in CorMedix (CRMD): Here's What You Should Know
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for CorMedix (CRMD) points to an 80.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Bet on 5 Top-Ranked Stocks With Rising P/E
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include The Chef's Warehouse, Life Time Group Holdings, The Honest Company, CorMedix and Boston Scientific.
Read More
All You Need to Know About CorMedix (CRMD) Rating Upgrade to Strong Buy
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
CorMedix (CRMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
Read More
Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report?
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
CRMD's Q3 momentum, fueled by DefenCath's strong uptake and Melinta's revenue boost, positions the stock for continued growth.
Read More
How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs add to momentum.
Read More
CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Negative
CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.
Read More
Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.
Read More
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
Read More
Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
CRMD's $300M Melinta buy adds seven therapies, easing reliance on DefenCath sales and bolstering growth in hospital-focused markets.
Read More
CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.
Read More
CorMedix Inc. (CRMD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
CorMedix Inc. (NASDAQ:CRMD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants Joseph Todisco - CEO & Director Conference Call Participants Ross Cohen Presentation Ross Cohen Okay. So thank you all for joining.
Read More
CorMedix (CRMD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Read More
Wall Street Analysts Think CorMedix (CRMD) Could Surge 32.04%: Read This Before Placing a Bet
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for CorMedix (CRMD) points to a 32% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
About CorMedix Inc. (CRMD)
- IPO Date 2010-05-13
- Website https://www.cormedix.com
- Industry Biotechnology
- CEO Joseph Todisco
- Employees 64